New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Jasper Therapeutics, Inc. (JSPR) vs Psyence Biomedical Ltd. (PBM)

Jasper Therapeutics, Inc. and Psyence Biomedical Ltd. are both Biotechnology companies. Jasper Therapeutics, Inc. and Psyence Biomedical Ltd. are of similar size ($11.9M and $10.9M). Jasper Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Psyence Biomedical Ltd. trades at 0.1×. Across the 8 metrics below, Jasper Therapeutics, Inc. leads on 6 and Psyence Biomedical Ltd. on 2.

Valuation

Metric JSPR PBM Biotechnology median
P/E n/m 0.13 8.49
P/S — — 8.56
P/B n/m 0.06 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.70 1.94 0.69
EV/Sales — — 8.00
Earnings yield (1,704.93%) 772.85% (35.81%)
Free cash flow yield (521.45%) (1,167.29%) (25.41%)

Profitability

Metric JSPR PBM Biotechnology median
Gross margin — — 70.18%
Operating margin — — 0.00%
Net margin — — 0.00%
Free cash flow margin — — 0.00%
Return on equity 244.79% 1.55% (51.58%)
Return on assets (153.74%) 1.45% (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric JSPR PBM Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) 19.22% (138.35%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric JSPR PBM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.59 8.09 4.79
Net debt to EBITDA 0.35 1.20 1.01

Dividend

Metric JSPR PBM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric JSPR PBM Biotechnology median
Market cap 11.92m 10.91m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack